Investigation of the Effects of Intranasal Oxytocin on Cognition and Emotion Processing in Frontotemporal Dementia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 2
- 主要终点
- Performance on Emotion Recognition Tasks
研究概览
简要总结
Investigations into the components of cognition damaged in frontotemporal dementia (FTD) demonstrate that patients with FTD show deficits in facial and verbal expression recognition, lack insight into what others think or might do (theory of mind skills), and in decision making tasks requiring processing of positive versus negative feedback. These cognitive functions are thought to be critical for appropriate social behavioural regulation (Blair, 2003). Recent studies in animal models and humans suggest that the neuropeptide oxytocin is an important mediator of social behavior and that oxytocin may facilitate emotion recognition, theory of mind processing, and prosocial behaviors (Donaldson and Young, 2008). Together, these findings suggest that upregulation of oxytocin dependent mechanisms of social and emotional cognition may be a valuable treatment approach in patients with FTD. The aim of this study is to determine how administration of intranasal oxytocin to patients with frontotemporal dementia affects behavior and processing of specific types of social and emotional information.The investigators' hypothesis is that oxytocin administration will improve emotional and social cognitive deficits in patients with FTD, resulting in improved decision making and behaviour.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 30 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Clinical diagnosis of probable Frontotemporal Dementia or Pick's disease
- •Caregiver available to participate in all study visits
排除标准
- •Severe language or memory deficits that preclude completion of the cognitive tasks
- •Females who are pregnant or breastfeeding (a pregnancy test will be done on females who have not completed menopause)
- •Uncontrolled hypertension
- •Bradycardia (rate <50 bpm) or tachycardia (rate > 100 bpm)
- •Current use of prostaglandins
- •Use of any investigational or experimental drug or device within the last 60 days prior to screening or within 5 half-lives of the experimental drug , whichever is longer
结局指标
主要结局
Performance on Emotion Recognition Tasks
时间窗: Day of treatment
次要结局
- Behavioural Ratings of Emotional Sensitivity and Repetitive Behaviours(One week following treatment)
- Side effects(1 week after treatment)
研究者
Elizabeth Finger
Cognitive Neurologist
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
